Edwin Kingsley

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

André Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh et al. · Blood · 2019 · 134 citations · Full text

Life Sciences, Oncology, Pharmacotherapy +12

ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Pier Luigi Zinzani, Christopher R. Flowers, Fontanet Bijou et al. · Journal of Clinical Oncology · 2023 · 98 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +11

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

Mazyar Shadman, Ian W. Flinn, Moshe Levy et al. · The Lancet Haematology · 2022 · 89 citations

Medicine, Oncology, Pharmacology +14

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

Tycel Phillips, Paul M. Barr, Steven I. Park et al. · Investigational New Drugs · 2018 · 78 citations · Full text

Medicine, Hematology, Pharmacology +16

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

Michael R. Savona, Kathryn S. Kolibaba, Paul Conkling et al. · American Journal of Hematology · 2018 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16